Indication
Serratia pneumonia
Serratia pneumonia is a lower respiratory tract infection caused by Gram-negative bacilli of the genus *Serratia*, most frequently *Serratia marcescens*. Read more about Serratia pneumonia
95 drugs 50 manufacturers
Drugs that treat it
Common Serratia pneumonia therapies.
CLAFORAN (cefotaxime sodium)
AMIKACIN SULFATE
TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE
GENTAMICIN SULFATE
AMIKACIN SULFATE
CEFTRIAXONE (ceftriaxone sodium)
AZTREONAM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSerratia pneumonia is a lower respiratory tract infection caused by Gram-negative bacilli of the genus *Serratia*, most frequently *Serratia marcescens*.
Primarily manifesting as a healthcare-associated or hospital-acquired pneumonia, it disproportionately affects hospitalized patients, individuals receiving mechanical ventilation, immunocompromised hosts, and patients with severe chronic cardiopulmonary disease.
Pathophysiologically, the infection is characterized by acute necrotizing bronchopneumonia, alveolar exudation, and pulmonary hemorrhage, frequently resulting in microabscess formation, lung cavitation, and empyema.
Affected patients typically present with acute fever, hypoxemia, purulent or blood-tinged sputum, and patchy bronchopneumonic infiltrates or consolidations on pulmonary imaging.
- nih.gov
Serratia pneumonia is a lower respiratory tract infection caused by Gram-negative bacilli of the genus *Serratia*, most frequently *Serratia marcescens* Pathophysiologically, the infection is characterized by acute necrotizing bronchopneumonia, alveolar exudation, and pulmonary hemorrhage, frequently resulting in microabscess formation, lung cavitation, and empyema Affected patients typically present with acute fever, hypoxemia, purulent or blood-tinged sputum, and patchy bronchopneumonic infilt...
- nih.gov
Serratia pneumonia is a lower respiratory tract infection caused by Gram-negative bacilli of the genus *Serratia*, most frequently *Serratia marcescens* Primarily manifesting as a healthcare-associated or hospital-acquired pneumonia, it disproportionately affects hospitalized patients, individuals receiving mechanical ventilation, immunocompromised hosts, and patients with severe chronic cardiopulmonary disease
- nih.gov
Primarily manifesting as a healthcare-associated or hospital-acquired pneumonia, it disproportionately affects hospitalized patients, individuals receiving mechanical ventilation, immunocompromised hosts, and patients with severe chronic cardiopulmonary disease
- nih.gov
Primarily manifesting as a healthcare-associated or hospital-acquired pneumonia, it disproportionately affects hospitalized patients, individuals receiving mechanical ventilation, immunocompromised hosts, and patients with severe chronic cardiopulmonary disease
- nih.gov
Pathophysiologically, the infection is characterized by acute necrotizing bronchopneumonia, alveolar exudation, and pulmonary hemorrhage, frequently resulting in microabscess formation, lung cavitation, and empyema Affected patients typically present with acute fever, hypoxemia, purulent or blood-tinged sputum, and patchy bronchopneumonic infiltrates or consolidations on pulmonary imaging
- nih.gov
Affected patients typically present with acute fever, hypoxemia, purulent or blood-tinged sputum, and patchy bronchopneumonic infiltrates or consolidations on pulmonary imaging
Personalize your experience
Follow Serratia pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.